Cargando…

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy

PURPOSE: Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (OS) benefits for combined radiochemotherapy. As mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steidl, Eike, Filipski, Katharina, Zeiner, Pia S., Wagner, Marlies, Fokas, Emmanouil, Forster, Marie-Therese, Ronellenfitsch, Michael W., Divé, Iris, Steinbach, Joachim P., Harter, Patrick N., Bähr, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236451/ https://www.ncbi.nlm.nih.gov/pubmed/33538917 http://dx.doi.org/10.1007/s00432-021-03511-y

Ejemplares similares

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
por: Zeiner, Pia S., et al.
Publicado: (2019)

Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma
por: Divé, Iris, et al.
Publicado: (2023)

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
por: Filipski, Katharina, et al.
Publicado: (2019)

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
por: Osman, Mohammed A
Publicado: (2014)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Single-shot bevacizumab for cerebral radiation injury
por: Voss, Martin, et al.
Publicado: (2021)

Temozolomide in paediatric high-grade glioma: a key for combination therapy?
por: Verschuur, A C, et al.
Publicado: (2004)

Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab
por: Voss, Martin, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network
por: Darlix, Amélie, et al.
Publicado: (2019)

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
por: Murphy, P S, et al.
Publicado: (2004)

Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy
por: Zhou, Xiaofeng, et al.
Publicado: (2016)

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A (1)H-Magnetic Resonance Spectroscopy Study
por: Steidl, Eike, et al.
Publicado: (2016)

Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment
por: Forster, Marie-Therese, et al.
Publicado: (2022)

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
por: Weller, J., et al.
Publicado: (2023)

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide
por: Koekkoek, Johan A. F., et al.
Publicado: (2015)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
por: McDuff, Susan G. R., et al.
Publicado: (2019)

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
por: Heinzen, Dennis, et al.
Publicado: (2019)

Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBV(max) nor vessel densities correlate between newly diagnosed and progressive glioblastoma
por: Steidl, Eike, et al.
Publicado: (2023)

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy
por: Guillevin, R, et al.
Publicado: (2011)

Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis
por: Xu, Weilin, et al.
Publicado: (2017)

ACT-18 SHOULD THE DOSE OF TEMOZOLOMIDE BE DECREASED FOR PATIENTS WITH HIGH-GRADE GLIOMAS WHO ARE ON HEMODIALYSIS?
por: Muto, Jun, et al.
Publicado: (2019)

Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients
por: Zhang, Baiwei, et al.
Publicado: (2021)

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis
por: Yang, Qunying, et al.
Publicado: (2021)

Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma
por: Zhong, Liyun, et al.
Publicado: (2022)

Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas
por: Tu, Zewei, et al.
Publicado: (2022)

Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis
por: Li, Guanglie, et al.
Publicado: (2023)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
por: Wan, Yanzhi, et al.
Publicado: (2023)

Inhibition of mTOR signaling protects human glioma cells from hypoxia-induced cell death in an autophagy-independent manner
por: Divé, Iris, et al.
Publicado: (2022)

Resilience in Lower Grade Glioma Patients
por: Fröhlich, Ellen, et al.
Publicado: (2022)

Prediction of Response to Temozolomide in Low‐Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics
por: Mazzocco, P, et al.
Publicado: (2015)

Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy; A Review Article
por: Koukourakis, Georgios V., et al.
Publicado: (2009)

Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas
por: Azzalin, Alberto, et al.
Publicado: (2017)

Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity
por: Tu, Zewei, et al.
Publicado: (2022)

The Effect of Β-Arrestin2 Overexpression Regarding Viability and Temozolomide Treatment in High-Grade Glioma Cells
por: OPRITA, ALEXANDRU, et al.
Publicado: (2022)

Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis
por: Luger, Anna-Luisa, et al.
Publicado: (2022)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2014)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2018)

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review
por: Hafazalla, Karim, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n5k1dgkt40g1o60tgj9u56rao5